HCW Biologics (HCWB) vs Jupiter Neurosciences (JUNS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Jupiter Neurosciences is the larger company by market cap ($3.8 million vs $3.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCWB | JUNS |
|---|---|---|
| Share price | $1.60 | $2.85 |
| Market cap | $3.58M | $3.76M |
| 1-day change | +4.58% | +2.89% |
| Forward P/E | — | 47.50 |
| EPS (TTM) | $-19.84 | $-18.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.57 | $135.75 |
| 52-week low | $1.50 | $2.25 |
| Distance from 52-week high | -94.20% | -97.90% |
| Analyst consensus | buy | — |
| Avg. price target upside | +2900.00% | — |
| Average volume | 376.23K | 983.10K |
| Shares outstanding | 2.24M | 1.32M |
| Employees | 35 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Jupiter Neurosciences
JUNS stock →Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
HCWB vs JUNS FAQ
Which is bigger, HCW Biologics or Jupiter Neurosciences?
Jupiter Neurosciences (JUNS) is larger, with a market capitalization of $3.76M compared with $3.58M for HCW Biologics (HCWB).
Are HCW Biologics and Jupiter Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.